NeurAxon was a private biopharmaceutical company based in Mississauga, Canada. The company was dedicated to developing novel pain therapeutics targeting neuronal nitric oxide synthase (nNOS). The company's pipeline included oral products aimed at treating conditions such as acute migraine, neuropathic pain, chronic daily headache, and inflammatory pain.
Pain management
CTI LSF I
Syndicate
n/a
December 9, 2009
Liquidated in 2015
Convertible Note
Neuraxon's lead asset targeted neuronal nitric oxide synthase (nNOS), an enzyme implicated in both pain modulation and central nervous system sensitization
